Protocol F3Z-MC-IOQV(a)
An Objective Assessment of Mealtime Bolus Insulin Behavior and Associated Factors
[STUDY_ID_REMOVED]
Approval Date: 20-Nov-2017
F3Z- MC-IOQV(a)  Clinical Protocol  Page 1 
LY8888AT     Confidential      Dated: 17 Nov 2017  Protocol F3Z- MC-IOQV (a) 
An Objective Assessment of Mealtime Bolus Insulin 
Behavior and Associated Factors 
 
Confidential Information  
The information contained in this document is confidential and is intended for the use of 
clinical investigators.  It is the property of Eli Lilly and Company or its subsidiaries and 
should not be copied by or distributed to persons not involved in the clinical investigation 
using the reusable  insulin injection  pen (LY8888AT ), unless such persons are bound by a 
confidentiality agreement with Eli Lilly and Company or its subsidiaries .   
Note to Regulatory Authorities:   This document may contain protected personal data 
and/or commercially confidential information exempt from public disclosure.  Eli Lilly and 
Company requests consultation regarding release/redaction prior to any public release.  In 
the United States, thi s document is subject to Freedom of Information Act (FOIA) 
Exemption 4 and may not be reproduced or otherwise disseminated without the written 
approval of Eli Lilly and Company or its subsidiaries.  
Clinical Investigation U sing the Reusable Insulin Injectio n Pen (LY8888AT ) 
Eli Lilly and Company  
Indianapolis, Indiana USA 46285  
Protocol Electronically Signed and Approved by Lilly on date provided below.  
 
Version  Approval Date  
Original  23 Sep 2017  
Amendment (a) 20 Nov 2017  
 
  
F3Z- MC-IOQV(a)  Clinical Protocol  Page 2 
LY8888AT     Confidential      Dated: 17 Nov 2017  Table of Contents  
Section  Page  
Protocol F3Z -MC-IOQV(a) An Objective Assessment of Mealtime Bolus 
Insulin Behavior and Associated Factors  ................................................................................1  
Table of Contents  .............................................................................................................................2  
1. Synopsis  ...................................................................................................................................8  
2. Schedule of Activities  ............................................................................................................11  
3. Introduction ...........................................................................................................................14  
3.1. Study Rationale  ................................................................................................................14  
3.2. Background .......................................................................................................................14  
3.3. Benefit/Risk Assessment  ..................................................................................................14  
4. Objectives and Endpoints  ......................................................................................................15  
5. Study Design  .........................................................................................................................16  
5.1. Overall Design  ..................................................................................................................16  
5.1.1.  Eligibility and Enrollment ........................................................................................16  
5.1.2.  Study Period 1  ..........................................................................................................17  
5.1.3.  Study Period 2  ..........................................................................................................17  
5.2. Number of Subjects  ..........................................................................................................18  
5.3. End of Study Definition....................................................................................................18  
5.4. Scientific Rationale for Study Design  ..............................................................................18  
5.5. Justification for Dose  ........................................................................................................18  
6. Study Population  ...................................................................................................................19  
6.1. Inclusion Criteria  ..............................................................................................................19  
6.2. Exclusion Criteria  .............................................................................................................20  
6.3. Lifestyle Restrictions  ........................................................................................................21  
6.4. Screen Failures  .................................................................................................................21  
7. Treatments  .............................................................................................................................22  
7.1. Treatments Administered  .................................................................................................22  
7.1.1.  Packaging and Labeling  ...........................................................................................22  
7.1.2.  Medical Devices  .......................................................................................................22  
7.1.2.1.  Continuous Glucose Monitoring ........................................................................22  
7.1.2.2.  Investigational Reusable Insulin Injection Pen ..................................................23  
7.2. Method of Treatment Assignment  ....................................................................................23  
7.2.1.  Selection and Timing of Doses  ................................................................................23  
7.3. Blinding ............................................................................................................................23  
7.4. Dosage Modification ........................................................................................................23  
F3Z- MC-IOQV(a)  Clinical Protocol  Page 3 
LY8888AT     Confidential      Dated: 17 Nov 2017  7.5. Preparation/Handling/Storage/Accountability  .................................................................23  
7.6. Treatment Compliance  .....................................................................................................24  
7.7. Concomitant Therapy  .......................................................................................................24  
7.8. Treatment after the End of the Study  ...............................................................................24  
7.8.1.  Treatment after Study Completion  ...........................................................................24  
8. Discontinuation Criteria  ........................................................................................................25  
8.1. Discontinuation from Study Treatment  ............................................................................25  
8.1.1.  Permanent Discontinuation from Study Treatment  .................................................25  
8.1.2.  Temporary Discontinuation from Study Treatment  .................................................25  
8.1.3.  Discontinuation of Inadvertently Enroll ed Subjects  ................................................25  
8.2. Discontinuation from the Study  ........................................................................................25  
8.3. Lost to Follow -Up ............................................................................................................26  
9. Study Assessments and Procedures  .......................................................................................27  
9.1. Efficacy Assessments  .......................................................................................................27  
9.1.1.  Primary Efficacy Assessments  .................................................................................27  
9.1.2.  Secondary Assessments  ...........................................................................................27  
9.1.3.  Exploratory Assessments  .........................................................................................28  
9.1.3.1.  Hypoglycemic Confidence Scale  .......................................................................28  
9.1.3.2.  Adult Low Blood Sugar Survey  .........................................................................28  
9.1.3.3.  The Big Five Inventory  ......................................................................................28  
9.1.3.4.  Health Problem Solving Scale  ............................................................................29  
9.1.3.5.  Pictorial Representation of Illness and Self Measure 
Revised II  ...........................................................................................................29  
9.1.3.6.  General Life Stress Scale  ...................................................................................29  
9.1.4.  Appropriateness of Assessments  ..............................................................................29  
9.2. Adverse Events and Device Complaints  ..........................................................................30  
9.2.1.  Serious Adverse Events  ...........................................................................................30  
9.2.1.1.  Severe Hypoglycemia  ........................................................................................32  
9.2.1.2.  Suspected Unexpected Serious Adverse Reactions  ...........................................32  
9.2.2.  Adverse Device Effects  ............................................................................................32  
9.2.3.  Complaint Handling  .................................................................................................32  
9.3. Treatment of Overdose  .....................................................................................................33  
9.4. Safety  ................................................................................................................................33  
9.4.1.  Laboratory Tests  ......................................................................................................33  
9.4.2.  Safety Monitoring ....................................................................................................33  
10. Statistical Considerations  ......................................................................................................34  
10.1.  Sample Size Determination  ..............................................................................................34  
10.2.  Populations for Analyses  ..................................................................................................34  
F3Z- MC-IOQV(a)  Clinical Protocol  Page 4 
LY8888AT     Confidential      Dated: 17 Nov 2017  10.3.  Statistical Analyses  ...........................................................................................................34  
10.3.1.  General Statistical Considerations  ...........................................................................34  
10.3.1.1.  Treatment Group Comparability  ........................................................................35  
10.3.1.2.  Subject Disposition  ............................................................................................35  
10.3.1.3.  Subject Characteristics  .......................................................................................35  
10.3.1.4.  Treatment Compliance  .......................................................................................35  
10.3.2.  Efficacy Analyses  ....................................................................................................35  
10.3.2.1.  Primary Analyses  ...............................................................................................35  
10.3.2.2.  Secondary Analyses  ...........................................................................................35  
10.3.3.  Safety Analyses  ........................................................................................................35  
10.3.4.  Other Analyses  .........................................................................................................35  
10.3.4.1.  Subgroup Analyses  .............................................................................................35  
10.3.5.  Interim Analyses  ......................................................................................................36  
11. References  .............................................................................................................................37  
12. Appendices  ............................................................................................................................39  
 
  
F3Z- MC-IOQV(a)  Clinical Protocol  Page 5 
LY8888AT     Confidential      Dated: 17 Nov 2017  List of Tables  
Table  Page  
Table IOQV.1.  Schedule of Activities  .......................................................................................12  
Table IOQV.2.  Objectives and Endpoints  ..................................................................................15  
Table IOQV.3.  Treatment Regimens  ..........................................................................................22  
Table IOQV.4.  Analysis Sets  .....................................................................................................34  
 
  
F3Z- MC-IOQV(a)  Clinical Protocol  Page 6 
LY8888AT     Confidential      Dated: 17 Nov 2017  List of Figures  
Figure  Page  
Figure  IOQV.1.  Illustration of study design for Clinical Protocol F3Z -MC-IOQV.  ...................16  
Figure  IOQV.2.  Example of a missed injection using a CGM profile.  .......................................27  
 
  
F3Z- MC-IOQV(a)  Clinical Protocol  Page 7 
LY8888AT     Confidential      Dated: 17 Nov 2017  List of Appendices  
Appendix  Page  
Appendix 1.  Abbreviations and Definitions ...........................................................................40  
Appendix 2.  Study Governance Considerations ....................................................................43  
Appendix 3.  Classification of Contraceptive Methods ..........................................................47  
Appendix 5.  Summary of Protocol Amendments ..................................................................49  
 
CCI
F3Z- MC-IOQV(a)  Clinical Protocol  Page 8 
LY8888AT     Confidential      Dated: 17 Nov 2017  1. Synopsis  
Title of Study :  
An Objective Assessment  of Mealtime Bolus Insulin Beha vior and Associated Factors  
Rationale :   
Current  diabetes management using basal/bolus insulin regimens require s a high level of patient  
engagement .  One -third of patients with type 1 diabetes (T1D) or type 2 diabetes (T2D) report ed 
insulin  omission/nonadherence at least once in the past month .  Of those  patients , there was an 
average of 3.3 days per month of insulin omission/nonadherence  (Peyrot et al. 2012) .  Patients 
often cite being too busy, fear of hypoglycemia, and concerns about weight gain as reasons for 
missing doses (Peyrot et al. 2012).  Downloaded dosage data from insulin pump users indicated 
that 65% of pump- using children/ adolescents with T1D missed 1 or more m ealtime insulin bolus 
doses per week, with an association between missed bolus doses and glycated hemoglobin 
(HbA1c) results (B urdick et al.  2004).  Prior to the development of insulin injection pens that 
track dose data, missed dosage data for multiple da ily injection users was obtained by patient 
survey results only .  The  reusable insulin injection  pen that records doses affords the opportunity 
to objectively gather omitted or suboptimal  insulin dose data  via pen download.  Additionally, 
the use of continuous glucose monitoring (CGM) allows an assessment of the impact  of bolus 
dosing  on short -term glycemic control.  
Objective(s)/Endpoints: 
Objectives  Endpoint (s) 
Primary  
• To objectively  estimate  the average number of days per 
month with a missed bolus dose in subject s with type 1 or 
type 2 diabetes with blinded CGM   
• The average number of days per month 
with a missed  bolus  dose 
Secondary  
• To estimate the average number of days per month with a 
missed bolus dose in subjects  with type 1 or  type 2 
diabetes with unblinded CGM  
• To estimate  the percent time -in-range in subject s with  type 
1 or type 2 diabet es with 
o Blinded CGM   
o Unblinded CGM  
• To estimate  the percent of missed bolus doses in subjec ts 
with type 1 or  type 2 diabetes with  
o Blinded CGM  
o Unblinded CGM  
• To estimate  the average  number of missed bolus doses per 
day in subject s with type 1 or type 2 diabe tes with  
o Blinded CGM  
o Unblinded CGM  
• To estimate the Missed and Suboptimal Bolus Dose 
(MSBD) in  subjects  with type 1 or type 2 diabet es with  
o Blinded CGM  
o Unblinded CGM   
• The average number of days per month 
with a missed bolus dose 
 
• Percent time -in-range (glucose >70 and 
≤180 mg/dL)  
 
 
• Percent of missed bolus doses per month 
  
• Average n umber of missed bolus doses per 
day 
 
 • The average number of MSBD events per 
month  
  
F3Z- MC-IOQV(a)  Clinical Protocol  Page 9 
LY8888AT     Confidential      Dated: 17 Nov 2017  Exploratory  
• To assess the association between MSBD rate and CGM  
alert settings   
• To evaluate characteristics associated with sho rt-term 
glycemic control in subjects  with type 1 or type 2 diabetes   
• To estimate the average number of days per month with a 
missed bolus dose in subjects  with type 1 diabetes with  
o Blinded CGM  
o Unblinded CGM  
• To estimate  the average number of days per month with a 
missed bolus dose in subject s with t ype 2 diabetes  with  
o Blinded CGM   
o Unblinded CGM   
• Correlation between MSBD rate and CGM 
alert settings   
• Outcome for each PRO  instrument * 
 
• The average number of days per month 
with a missed bolus dose 
 
 
• The average number of days per month with a missed bolus dose 
 
Abbreviations:  CGM = continuous glucose monitoring; PRO = patient- reported outcome s. 
* if available for use  
 
Summary of Study Design:    
Study F3Z-MC-IOQV (IOQV) is a  12-week,  multicenter, single -arm, outpatient , exploratory 
study with 2 study period s in subject s with T1D or T2D , respectively , using an investigational  
reusable insulin injection  pen and a commercially available CGM device .  Subjects  participating 
in the study will follow an appropriate prescribed bolus  insulin regimen suitable for their disease 
state using insulin lispro 100 units/mL injected via the reusable insulin injection pen.  During the 
study, subjects will have their glucose monitored via a commercially available CGM device, 
which will be blinde d during Study Period 1 and unblinded during Study P eriod  2.  The main 
purpose of the  study is to estimate missed bolus insulin doses  in subject s with T1D or T2D.   
Treatment Arm and Duration:    
Study IOQV is a 12 -week study with a sin gle treatment arm.  A ll subject s will administer insulin 
lispro  U-100 (100 units/mL)  using the investigational reusable insulin injection  pen.  All subjects 
will use a commercially available CGM device during  the study.  
Number of Subject s:   
Screened :  80 subject s 
Enrolled:  68 subject s 
Completed:  50 subject s 
Statistical Analysis :  
The primary objective  of Study IOQV is  to objectively measure missed bolus doses in subject s 
with T1D or T2D with blinded CGM.  The primary endpoint  is the average number of days per 
month with a missed bolus dose, which will be estimated  along with the 95% confidence 
interval .  Secondary  analyses will  estimate the average number of days per month with a missed 
bolus dose with unblinded CGM, the percent time in glucose range, the percent of missed bolus doses, and the missed and suboptimal bolus dose (MSBD) by blinded and unblinded CGM.  Exploratory analyses will evaluate the correlation between MSBD and CGM alert settings; graphically explore subject characte ristics associated with short- term glycemic control; estimate 
F3Z- MC-IOQV(a)  Clinical Protocol  Page 10 
LY8888AT     Confidential      Dated: 17 Nov 2017  the average number of days per month with a missed bolus dose by type of diabetes (T1D, T2D) 
and CGM (blinded, unblinded) . 
Given the exploratory  nature of Study IOQV, the analyses will be primar ily descriptive.  These 
will include mean, standard deviation, minimum, median, and maximum for continuous variables, and frequency and percentage for categorical variables.    
F3Z- MC-IOQV(a)  Clinical Protocol  Page 11 
LY8888AT     Confidential      Dated: 17 Nov 2017  2. Schedule of Activities  
 
F3Z- MC-IOQV(a)  Clinical Protocol  Page 12 
LY8888AT     Confidential      Dated: 17 Nov 2017  Table IOQV .1. Schedule of Activities 
 Study Period 1  
Blinded CGM  Study Period 2  
Unblinded CGM    
Procedure 
Weeks from Enrollment  Screening/  
Enrollment  
V1 
0W V2 
3W V3 
6W V4 
9W End of Study  
V5 
12W  Early  
D/C Notes  
Visit Window  N/A 3D 3D 3D 3D N/A Allowable deviation +/ - days or 
week s from scheduled visit.  
Office or home visit X X X X X X  
Informed consent  X       
Inclusion and exclusion criteria  X       
Demography  X       
Height and weight  X       
Medical history  X       
Current medical conditions  X      Including baseline diabetes disease 
characteristics  
Pregnancy test  X       
Prescribed insulin regimen  X      Currently prescribed basal and bolus 
insulin regimen  
Concomitant medication review  X X X X X X  
Enrollment  X       
HbA1c blood draw  a X  X  X X  
Pen dispensing  X      Record pen identification for 
dispensed pens  
Pen training and start pen X       
Confirm pen operation   X X X X   
Pen collection/ return      X X  
CGM and glucose meter training  X       
CGM and pen data download   X X X X X  
Adjust CGM alert settings     X    
Hypoglycemic Confidence Scale  X  X  X X  
Adult Low Blood Sugar Survey  X  X  X X  
F3Z- MC-IOQV(a)  Clinical Protocol  Page 13 
LY8888AT     Confidential      Dated: 17 Nov 2017   Study Period 1  
Blinded CGM  Study Period 2  
Unblinded CGM    
The Big Five Inventory  X       
Health Problem Solving Scale  X  X  X X  
Pictorial Representation of Illness and Self Measure  X  X  X X  
General Life Stress Scale  X  X  X X  
AE and SAE review   X X X X X  
Product complaint review   X X X X X  
Abbreviations:  AE = adverse event; CGM = continuous glucose monitoring;  D = days; D/C = discontinuation; HbA1c = glycated hemoglobin;  N/A = not 
applicable; SAE = serious adverse event; V = visit; W = week . 
a HbA1c testing will be  performed  by local laboratories.  
 
 
F3Z- MC-IOQV(a)  Clinical Protocol  Page 14 
LY8888AT     Confidential      Dated: 17 Nov 2017  
 3. Introduction  
3.1. Study Rationale  
Current  diabetes management using basal/bolus insulin regimens require s a high level of patient 
engagement .  One -third of patients with type 1 diabetes (T1D) or type 2 diabetes (T2D) report ed 
insulin omission/nonadherence at least once in the past month.  Of those patients, there was an 
average of 3.3 days per month of insulin omission/nonadherence (Peyrot et al. 2012).  Patients often cite being too busy, fear of hypoglycemia, and concerns about weight gain as reasons for missing doses (Pe yrot et al. 2012).  Downloaded dosage data from insulin pump users indicated 
that 65% of pump- using children/ adolescents with T1D missed 1 or more mealtime insulin bolus 
doses per week, with an association between missed bolus doses and glycated hemoglobin  
(HbA1c) results (Bur dick et al.  2004).  Prior to the development of insulin injection pens  that 
track dose data, missed dosage  data for multiple daily injection users was obtained by patient 
survey  results  only.  The investigational reusable insulin injection pen (hereafter referred to as 
“pen”) affords the opportunity to objectively gather omitted or suboptimal  insulin dose data via 
pen download.  Additionally, the continuous glucose monitoring (CGM) allows an assessment of the impac t of bolus dosing on short -term glycemic control. 
Study F3Z-MC-IOQV (IOQV) is an exploratory  study to  objectively estimate the average 
number of days per month subjects have a missed bolus dose in subject s with T1D or T2D  with 
blinded CGM .  In addition, th e study will explore any differences in missed bolus insulin doses  
by diabetes type, by CGM (blinded, unblinded), and by subject characteristics.  Study IOQV will utilize  data from the pen to obtain bolus dose data  (including amount and time of dose ), along 
with blinded and unblinded CGM to assess short -term glycemic control .   
3.2. Background  
Glycemic control is the ultimate goal of any diabetes treatment regimen.  However, many subject s with T1D and T2D continue to have poor glycemic control in large pa rt due to lower 
adherence to their prescribed diabetes treatment regimen due to reasons including diabetes knowledge, personal -perceived  control, diabetes distress, and regimen -related distress,  among 
others ( Al-Qazaz et al. 2011; Cummings et al. 2014;  Gon zalez  et al . 2015).  Many previous 
analyses have been performed by survey results and self -reporting .  The pen, CGM , and 
patient -reported outcomes  (PRO) data can document insulin dosing and blood glucose, and 
inform behavior concerning  insulin dosing .   
3.3. Benefit/Risk Assessment  
More information about the known and expected benefits, risks, serious adverse events (SAEs) , 
and reasonably anticipated adverse events (AEs) can be found in the insulin lispro  100 units/mL  
United States Package Insert (USPI) , and p en Investigat or’s Brochure  (IB). 
F3Z- MC-IOQV(a)  Clinical Protocol  Page 15 
LY8888AT     Confidential      Dated: 17 Nov 2017  
 4. Objectives and Endpoints  
Table IOQV.2  shows the objectives and endpoints of the study.  
Table IOQV .2. Objectives and Endpoints 
Objectives  Endpoint (s) 
Primary  
• To objectively estimate  the average number of days per 
month with a missed bolus dose in subject s with type 1 or 
type 2 diabetes with blinded CGM   
• The average number of days per month 
with a missed  bolus  dose 
Secondary  
• To estimate the average number of days per month with a 
missed bolus dose in subject s with t ype 1 or  type 2 
diabetes with unblinded CGM  
• To estimate  the percent time -in-range in subject s with type 
1 or type 2 diabetes with  
o Blinded CGM  
o Unblinded CGM  
• To estimate  the percent of missed bolus doses in subject s 
with type 1 or  type 2 diabetes with  
o Blinded CGM  
o Unblinded CGM  
• To estimate the average number of missed bolus doses per 
day in subject s with type 1 or type 2 diabetes with 
o Blinded CGM  
o Unblinded CGM  
• To estimate the Missed and Suboptimal Bolus Dose 
(MSBD) in  subject s with type 1 or type 2 diabet es with  
o Blinded CGM  
o Unblinded CGM   
• The average number of days per month 
with a missed bolus dose 
  
• Percent time -in-range (glucose >70 and 
≤180 mg/dL)  
 
• Percent of missed bolus doses per month 
 
 
 • Average number of missed bolus doses 
per day  
 
 
• The average number of MSBD events per 
month  
Exploratory  
• To assess the association between MSBD rate and CGM 
alert settings  
• To evaluate characteristics associated with short -term 
glycemic control in subject s with type 1 or type 2 diabetes   
• To estimate the average number of days per month with a 
missed bolus dose in subject s with t ype 1 diabetes with  
o Blinded CGM  
o Unblinded CGM  
• To estimate  the average number of days per month with a 
missed bolus dose in subject s with t ype 2 diabetes  with  
o Blinded CGM  
o Unblinded CGM   
• Correlation between MSBD rate and CGM alert settings  
• Outcome for each PRO instrument*  
 
• The average number of days per month with a missed bolus dose 
  
• The average number of days per month 
with a missed bolus dose 
 
Abbreviations:  CGM = continuous glucose monitoring; PRO = patient- reported outcome s. 
* if available for use  
F3Z- MC-IOQV(a)  Clinical Protocol  Page 16  
LY8888AT     Confidential      Dated: 17 Nov 2017  
 5. Study Design  
5.1. Overall  Design  
Study IOQV is  a 12- week,  multicenter, single -arm, outpatient , exploratory study with 2 study 
periods in subject s with T1D or T2D .  Study IOQV will use  an investigational pen  injector , 
which captures bolus insulin doses, and a commercially available CGM device.  Subject s 
participating in the study will follow an appropriate prescribed insulin regimen s uitable for their 
disease state using insulin lispro  100 units/mL  injected via the pen.  During the study, subject s 
will have t heir glucose  monitored via the CGM device, which will be blinded during Study 
Period 1 and unblinded during Study P eriod  2.  In addition, subject s will take PRO evaluations to 
assess potential behaviors related to short- term glycemic control.    
Study governance considerations are described in detail in Appendix 2. 
One study center will be managed by Sponsor designee , using telemedicine, mobile 
study nurses, and an electronic application called .  Further details about management of 
this study center by  are provided in Appendix 4.  
Figure  IOQV.1  illustrates the study design.   
 
 
*Pen and Continuous Glucose monitor (CGM) Data collection 
Note:  All visits are in  clinic/home  
Figure IOQV.1. Illustration of study design for Clinical Protocol F3Z -MC-IOQV.  
5.1.1.  Eligibility and Enrollment  
Subject s will be screened  at Visit 1 (Week 0)  for the assessment of enrollment eligibility.  
Screening assessmen ts are outlined in the Schedule of Activities ( SOA) (Table  IOQV. 1).  
Patients who pass screening assessments based on the inclusion and exclusion criteria set forth in 
Section s 6.1 and 6.2 are eligible to be  enrolled in the study.   
CCI
CCI
CCI
F3Z- MC-IOQV(a)  Clinical Protocol  Page 17 
LY8888AT     Confidential      Dated: 17 Nov 2017  
 5.1.2.  Study Period 1  
At Visit 1  (Week 0) , informed consent will be obtained from each subject.   
Each subject  will have a unique  subject  number assigned, additional eligibility requirements 
evaluated, and laboratory tests will be performed as outlined in the SOA  (Table IOQV. 1).  After 
confirming eligibility  (Visit 1) , subjects will be train ed on the devices to be used in the study.  
Subjects will be trained by the study  site to self -insert the CGM sensor .  If the subject cannot 
self-insert the CGM sensor, the site/study personnel will insert the CGM sensor .  Subjects  will be 
blinded to their CGM data .  Subjects will continue their routine blood glucose monitoring as 
needed while using the bl inded CGM device.  However, subject s must monitor their blood 
glucose at least twice per day using a provided glucose monitor to calibrate the CGM device 
(Section  7.1.2.1) . 
Subject s will begin using the  pen to inject insulin lispro 100 units/mL and the blinded C GM 
device as directed at Visit 1 (Week 0)  after training.   Subjects entering the study taking 
rapid -acting insulin analog  other than insulin lispro 100 units /mL should be switched to insulin 
lispro 100 units/mL using a 1:1 dose conversion unless  there are safety concerns as identified by 
the investigator.  Subjects should continue their prestudy basal insulin and concomitant anti -
hyperglycemic therapy  and the investigator may adjust the insulin and other diabetes therapy as 
needed.  In addition, the blinded CGM device will record the subject ’s glucose  during Study 
Period  1 as outlined in the SOA . 
A training  checklist for the pen and the CGM devi ce will be provided to investigators to aid in 
subject  training.  This training includes, but is not limited to, the operation of the pen and CGM 
device, CGM device calibration, clearing CGM alerts, and other study procedures.  Subjects may be retrained on  the aforementioned items if deemed appropriate by the study site.   See Section 
7.1.2 for more information regarding the devices used in the study .  
Subjects will be instructed to insert a new sensor weekly and recalibrate the CGM device throughout the study.  At  Visit 2 (Week 3)  and Visit 3 (Week 6), subjects will have their blinded 
CGM data and pen data downloaded by the study site personnel . 
5.1.3.  Study  Period 2  
Following the completion of Visit 3 (Week 6)  assessments , subject s will begin S tudy Period  2 
and will be unblinded to their CGM data.  
At Visit 4 (Week 9) , subjects will have their unblinded CGM data and pen data downloaded by 
the study site personnel and any required adjustments to their CGM device alarms  will be 
performed  by the study site .  Insulin adjustment recomme ndations will be provided by the 
investigator and designated staff based o n the available glucose and insulin data.  At Visit 5 
(Week 12) , subject s will complete their participation in the study, and  the site will download all 
of the pen and CGM data  since the last visit.  
F3Z- MC-IOQV(a)  Clinical Protocol  Page 18 
LY8888AT     Confidential      Dated: 17 Nov 2017  
 5.2. Number of Subject s 
Approximately  80 patient s will be screened to achieve approximately  68 enrolled  leading to 
approximately  50 evaluable subjects for Study IOQV .  A minimum of 28 patients and a 
maximum of 40 patients each of T 1D and T 2D will be enrolled.  
5.3. End of Study  Definition  
End of the study  is the date of the last visit shown in the SOA (Section 2)  for the last subject . 
5.4. Scientific Rationale for Study Design 
This exploratory  study  objectively estimate s bolus doses and their relationship to short -term 
glycemic control and PROs.  The  pen allows for objective collect ion of data that can be assessed 
as missed or suboptimal doses.  Prior to a downloadable pen, other investigators have co llected 
bolus data for multiple daily injection users subjectively from patient and/or healthcare 
professional  reports .  There is no standard of care or comparat or arm because the primary 
objective of this study  is to objectively estimate  missed bolus dose s.  Therefore, the second half 
of Study Period 1 (Visit 2 [Week 3] to Visit 3 [Week 6]) will be used for analyses  with blinded 
CGM .  The study duration of 12 weeks (2 parts of 6 weeks each ) is adequate  based on the 
inclusion criteria  of 3 or more bolus doses daily  for the assessment of  missed bolus doses .  Each 
enrolled subject must be  on a mealtime bolus insulin regimen with each individual bolus insulin 
dose being <40 units  (Section 6.1) .  Adult T1D and T2D populations were chosen to explore  
whether there might be differences based on disease type.  
5.5. Justification for Dose  
The dose of insulin lispro 100 units/mL to be used in the study will be different for each subject  
according to their insulin needs.  Subjects will be instructed to continue their prestudy basal insulin  and concomitant antihyperglycemic therapy .  The investigator can make b asal and bolus 
insulin adjustments as needed .  The prescribed insulin regimen will be determined from the 
subject ’s medical records  at the start of the study , and any dosage adjustments needed during the 
study shall be documented for analysis (Section 7.4) .  Subject’s basal insulin and concomitant 
antihyperglycemic therapy may be adjusted as needed per investigator’s discretion as needed for safety (Section 7.7) .   
F3Z- MC-IOQV(a)  Clinical Protocol  Page 19 
LY8888AT     Confidential      Dated: 17 Nov 2017  
 6. Study Population 
Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as 
protocol waivers or exemptions, are not permitted.  
6.1. Inclusion Criteria  
Patients are eligible to participate  in the study only if they meet all of the following criteria at 
screening : 
Type of Subject  and Disease Characteristics  
[1] Subject s with a T1D or T2D  diagnosis:  
i) Mealtime bolus dose insulin  (≥3 dose s). 
ii) Each individual bolus insulin dose must be <40 units . 
iii) Subjects must be taking a stable insulin dose regimen per the investigator’s 
judgement for the 3 months preceding screening.  
[2] Subject s must be taking a bolus insulin analog ( for example insulin lispro [U -
100]/[U-200], insulin aspart, or insulin glulisine) .  In addition, the subject  
must be  able to switch to insulin lispro U -100 for the duration of the trial  per 
the investigator’s judgement , if taking a bolus insulin analog other than insulin 
lispro U -100.  
[3] Subjects must have a HbA1c ≥8.0% in the last 6 months . 
[4] Subjects with T1D must be ≥21 to ≤ 65 years of age at screening.  Subjects with T2D 
must be ≥35 to ≤ 65 years of age at screening.  
Subject  Characteristics  
[5a] Male subject s: 
 No male contraception required except in compliance with specific local government study requirements. 
[5b] Female subject s: 
Women of non- childbearing and childbearing potential . Women of childbearing  
potential are defined as:  
Female subjects as any female who has experienced menarche and who is NOT 
permanently sterile or postmenopausal. Postmenopausal is defined as 12 consecutive months with no menses without an alternative medical cause.  These 
subje cts: 
I. Must agree to use 1 highly effective method of contraception, or a 
combination of 2 effective methods of contraception for the entirety of the study ( Appendix 3)  
F3Z- MC-IOQV(a)  Clinical Protocol  Page 20 
LY8888AT     Confidential      Dated: 17 Nov 2017  
 II. Must test negative for pregnancy as indicated by a negative serum  or urine  
pregnancy test  at screening . 
[6] Subject s with prior CGM /flash glucose monitoring experience must have 
stopped CGM /flash glucose monitoring  ≥3 months  prior to enrollment.   
[7] Study materials and devices will only be provided in English.  Subjects must 
be comfortable with understanding the English language . 
Informed Consent  
[8] Are able and willing to give signed informed consent . 
6.2. Exclusion Criteria  
Patients will be excluded from study enrollment if they meet any of the following criteria:  
Medical Conditions  
[9] Subject s with known tape/adhesive allergies with CGM sensors. 
[10] Subject s with  medical conditions,  visual, ph ysical, psychiatric, or cogniti ve 
impairment(s) that may preclude the ability to participate in the trial per the investigator’s discretion . 
[11] Have a documented medical history of or obvious clinical signs or symptoms 
of liver disease, acute or chronic hepatitis, or a history of alanine 
aminotransferase or aspartate aminotransferase levels ≥3 times the upper limit 
of the reference range within the last 6 months before screening . 
[12] Have documented medical history of chronic kidney disease stage 4 and 
higher within the last 6 mon ths before screening or history of renal 
transplantation . 
[13] Have active malignancy . 
[14] Are pregnant  or planning to become pregnant . 
[15] Are on or are intending on beginning a weight loss program .  
Prior/Concomitant Therapy  
[16] Subjects with T1D who have taken off- label antihyperglycemic agents within 
3 months  prior to screening.  
[17] Have received insulin by  continuous subcutaneous insulin infusion in  the 
3 months prior to screening.  
[18] Subject s taking opioid medications  at screening for medically invalid  reasons 
or at doses considered excessive for the treated condition per the investigator’s discretion . 
[19] Subject s on routine use of acetaminophen at screening  per the investigator’s 
judgement .  
F3Z- MC-IOQV(a)  Clinical Protocol  Page 21 
LY8888AT     Confidential      Dated: 17 Nov 2017  
 [20] Currently undergoing systemic treatment with : 
• Immunosuppressive medication. 
• Chronic (lasting longer than 2 weeks) systemic glucocorticoid therapy 
(excluding topical and inhaled preparations) or have received such therapy 
within 2 weeks immediately before Visit 1 (Week 0).  
Prior/Concurrent Clinical Tria l Experience  
[21] Are currently enrolled in any other clinical study involving an investigational 
product or any other type of medical research judged not to be scientifically or medically compatible with this study . 
[22] Have participated, within the last  30 days , in a clinical study involving an 
investigational product.  If the previous investigational product has a long 
half-life, 5 half -lives or 30 days  (whichever is longer) should have passed.  
[23] Have previously completed or withdrawn from this study .   
Other Exclusions  
[24] Are investigator site personnel directly affiliated with this study and/or their 
immediate families.  Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted.  
[25] Are Lilly employ ees or are employees of any third party  involved in the study 
who require exclusion of their employees . 
[26] Are unwilling or unable to comply with the use of a data collection device to 
directly record data from the subject . 
6.3. Lifestyle Restrictions  
Subject s must have a stable lifestyle with no changes to dietary or exercise habits during the 
course of the study.  
6.4. Screen Failures  
Individuals who do not meet the criteria for participation in this study (screen failure)  may be 
rescreened.   
F3Z- MC-IOQV(a)  Clinical Protocol  Page 22  
LY8888AT     Confidential      Dated: 17 Nov 2017  
 7. Treatments 
7.1. Treatments Administered  
This study involves the treatment  of subject s with diabetes with marketed insulin lispro 
(100 units/mL ) administered by the pen .  Table IOQV. 3 shows the treatment regimens.   Subjects 
will continue their pre -study concomitant anti -hyperglycemic medication  and basal insulin 
therapies during the study. 
Table IOQV .3. Treatment Regimens  
Study Period 1  Study Period 2  
Insulin lispro doses as prescribed delivered via the pen.  
CGM data blinded.  Insulin lispro doses as prescribed delivered via the pen.  
CGM data unblinded.  
Abbreviation:  CGM = continuous glucose monitoring . 
 
The investigator or his/her designee is responsible for the following: 
• explaining the correct use of the pen , the commercially available CGM device, 
and the glucometer  to the subject  or the subject’s legal representative.  
• maintaining  accurate records of all pens, medication  vouchers/pharmacy cards, 
and device dispensing and collection. 
• at the end of the study, all pens , the CGM device, and glucose meter  must be 
returned to Lilly or its designee.   
7.1.1.  Packaging and Labeling 
Clinical study materials will be labeled according to U nited States (U S) regulatory requirements. 
7.1.2.  Medical Devices  
The medical device provided for use in the study is the investigational reusable insulin injection 
pen, which collects dose administration information.  The other devices provided for use during the study are  a commercially available CGM device (  
 and a glucose meter .   
As each subject completes the study, accountability will be completed and the returned items 
will be stored as instructed .  Detailed information about this process will be available as part of 
site’s working manual. 
7.1.2.1.  Continuous Glucose Monitoring  
The commercially available CGM  device that will be used during the study is the  
, which  consists of a glucose sensor, data transmitter, and data receiver that assesses 
interstitial glucose readings every 5 minutes.  The  can be blinded or 
unblinded.  The  should be calibrated at least once every 12 hours by a finger 
stick  blood glucose reading from the provided glucose meter.  The calibration of the  
 should be done during both study periods when the CGM system is in use. 
CCI
CCI
CCI
CCI
CCI
F3Z- MC-IOQV(a)  Clinical Protocol  Page 23 
LY8888AT     Confidential      Dated: 17 Nov 2017  
 7.1.2.2.  Investigational Reusable Insulin I njection Pen  
The insulin injection devic e to be used in Study IOQV is an investigational reusable pen injector 
for the delivery of a subcutaneous injection of insulin using the standard Lilly 3 mL Humalog 
U-100 glass cartridges.  The pen is a variable dose device for use in patients with T1D or T2D.  
The pen dials in 1- unit increments with a 60 unit maximum dose, and requires a new pen needle 
for each injection.  The pen contains an organic light -emitting diode display and memory 
function which allows for insufficient remaining dose detection (while displaying the remaining partial dose), last dose display (time since last dose and units delivered), a full dose history in memory, and “Injection Complete” prompt.  The pen contains electronics with the capability to store dosage data and download the data by the study site personnel.  Due to the investigational nature of the reusable insulin injection pen, this study is also following 21 CFR 812 guidelines for investigational devices.  
7.2. Method of Treatment  Assignment  
Subject s who meet all inclusion/exclusion  criteria  (Sections 6.1 and 6.2)  will be enrolled into the 
study at Visit 1 (Week 0) .  This study is an  open- label, single -arm study  for which all  subject s 
are receiving insulin lispro 100 units/mL .   
7.2.1.  Selection and Timing of Doses  
The doses will be administered according to the subject’s usual practices .  The actual  dose and 
time of all dose administrations will be recorded by the pen and downloaded by study site personnel .  Subjects will continue their prestudy basal insulin and concomitant 
antihyperglycemic therapy and the investigator may make insulin dose adjustments as indicated.   
7.3. Blinding 
This is an open- label study.   Subject s and study personnel will not be blinded to insulin lispro 
100 units/mL  administered via the pen .  Subjects will not have access  to their historical bolus 
dosing data from  the pen with the exception of the display indicating the duration since their last 
bolus dose .  Additionally during Study Period 1, subject s will be blinded to their  CGM readings  
(Figure  IOQV. 1).  Subject s and the study personnel will be unblinded to the subject’s CGM data 
during Study Period 2.  
7.4. Dosage Modification  
Insulin dosage modifications are not  required during  the study  but m ay be indicated.  Therefore, 
insulin adjustment s are allowed based on the investigator’s medical judgement  using  the 
available glucose and insulin data.  Subject s who are adjusted to a single  bolus insulin dose of  
>40 units per injection will be discontinued from the study .   
7.5. Preparation/Handling/Storage/Accountability  
The investigator or his/her designee is responsible for the following:  
• Device t raining on the pen, CGM system , and glucometer . 
• Completion of the checklist for all  device training.  
F3Z- MC-IOQV(a)  Clinical Protocol  Page 24 
LY8888AT     Confidential      Dated: 17 Nov 2017  
 • Ensuring that only subjects  receive study treatment vouchers .  
• The investigator, institution, or the head of the medical institution (where 
applicable) is responsible for study treatment  voucher  accountability, 
reconciliation, and record maintenance (such as receipt, reconciliation , and final 
disposition records).  
7.6. Treatment Compliance  
Compliance of pen utilization will be assessed at each visit .  To avoid missing data, the pen and 
CGM data will be  downloaded at predetermined time  points described in the SOA .   
7.7. Concomitant Therapy  
Other concomitant therapies that are part of routine care are allowed and can be used during the 
study at the investigator’s discretion.   A list of medications not allowed will be provided 
separately.  Any change in the list of medications  not allowed will be communicated to 
investigators, and will not constitute a protocol amendment . 
A subject’s concomitant antihyperglycemic therapy may be adjusted as needed per investigator’s 
discretion for safety .  
7.8. Treatment after the End of the Study  
7.8.1.  Treatment after Study Completion 
The pen  or insulin lispro will not be made available to  study participants  after conclusion of the 
study .  Subjects will resume their standard insulin therapy at the completion of the study.  
F3Z- MC-IOQV(a)  Clinical Protocol  Page 25 
LY8888AT     Confidential      Dated: 17 Nov 2017  
 8. Discontinuation Criteria  
8.1. Discontinuation from Study Treatment  
8.1.1.  Permanent Discontinuation from Study Treatment  
Discontinuation from study treatment (i.e., the pen) for a total of >3 days would lead to 
permanent discontinuation from study treatment as the purpose of the study is to collect data on 
bolus dosing .  If a subject is permanently  discontinued from study treatment, they will also be 
discontinued from the study.  
8.1.2.  Temporary Discontinuation from Study Treatment  
Subject s may temporarily discontinue study treatment for a total of ≤3 days  due to temporary 
hospitalization, medical procedure, loss of the pen, or per the investiga tor’s judgement.   
8.1.3.  Discontinuation of Inadvertently Enrolled Subject s 
If the sponsor or investigator identifies  a subject  who did not meet enrollment criteria and was 
inadvertently enrolled, then the subject  should be permanently  discontinued from study 
treatment.  Safety follow -up is as outlined in the SOA  (Table IOQV. 1), Section 9.2 (Adverse 
Events), and Section 9.4 (Safety ) of the protocol.  
8.2. Discontinuation from the Study  
Subject s will be discontinued in the following circumstances :   
• if the subject becomes pregnant during the study as determined by a se rum or 
urine pregnancy test performed at the investigator’s suspicion of possible 
pregnancy.  
• enrollment in any other clinical study involving an investigational product or 
enrollment in any other type of medical research as judged by the sponsor not 
to be scientifically or medically compatible with this study . 
• for medical, safety, regulatory, or other reasons consistent with applicable 
laws, regulations, and good clinical practice (GCP) . 
• subject s who are adjusted to a single  bolus insulin dose of >40 units per 
injection . 
• if the subject discontinues study treatment for a total of >3  days.  
• Investigator D ecision  
o the investigator decides that the  subject  should be discontinued from the 
study . 
o if the investigator deems it necessary to stop insulin lispro  treatment.  
• Subject D ecision  
F3Z- MC-IOQV(a)  Clinical Protocol  Page 26 
LY8888AT     Confidential      Dated: 17 Nov 2017  
 o the subject  or the subject ’s designee requests to be withdrawn from the 
study . 
• Sponsor Decision  
o if the subject  loses or otherwise renders the pen (and its replacement pen) 
inoperable, the sponsor may discontinue that subject  from the study.  
o the sponsor decides to stop the study . 
Subject s discontinuing from the study prematurely for any reason should complete AE and other 
safety follow -up per Section  2 (SOA), Section  9.2 (Adverse Events) , and Section 9.4 (Safety ) of 
this protocol. 
8.3. Lost to Follow -Up 
A subject  will be considered lost to follow -up if he or she repeatedly fails to attend  scheduled 
visits and is unable to be contacted by the study site.  Site personnel are expected to make 
diligent attempts to contact subject s who fail to return for a schedul ed visit or were otherwise 
unable to be followed up by the site.  
F3Z- MC-IOQV(a)  Clinical Protocol  Page 27 
LY8888AT     Confidential      Dated: 17 Nov 2017  
 9. Study Assessments and Procedures  
Section 2 lists the SOA, with the study procedures and their timing (including tolerance limits for 
timing).  
9.1. Efficacy Assessments  
9.1.1.  Primary  Efficacy  Assessments  
The primary efficacy assessment objectivel y estimate s the average number of days per month 
with a missed bo lus dose in subject s with type 1 or type 2 diabetes using blinded CGM 
measurements and the pen.  Missed bolus doses will be determined by the glucose excursion as measured by the CGM.  
• A subje ct is counted as missing 1 injection , if the subject  does not have any injection record 
during the 1 -hour interval prior to a glucose  excursion  (≥80 mg /dL) in the 2-hour 
postprandial interval .   
Example :  In the theoretical CGM profile ( Figure  IOQV. 2), 2 glucose excursions 
≥80 mg /dL within a 2 -hour interval  are observed :   
o nadir  at 11  am and peak at 12  pm,  
o nadir  at 1:30 pm and high at  2:15 pm.   
If the associated insulin pen data show no injection between 10  am and 11 am and 1 
injection between 12:30 pm and 1:30 pm, then the subject  has 1 missed injection 
corresponding to the 11 am -12 pm glucose excursion. 
 
Figure IOQV.2 . Example of a m issed injection using a CGM profile . 
9.1.2.  Secondary Assessments 
Study IOQV will have 5 secondary efficacy measures as described  in Table IOQV. 2.  The first 
secondary objective  is similar to the primary objective ( Section 9.1.1) e xcept that the information 
to be analyzed will be using  unblinded CGM data.  Missed bolus doses will be determined by the 
glucose excursion as measured by the unblinded CGM.   

F3Z- MC-IOQV(a)  Clinical Protocol  Page 28 
LY8888AT     Confidential      Dated: 17 Nov 2017  
 Study IOQV will also estimate the percent time -in-range in subjects with T1D  or T2D  using 
blinded and unblinded CGM data.  The glucose range for this analysis is >70 and ≤180 mg/dL.  
In addition, the percent of missed bolus doses per month and the average number of missed bolus doses per day will be estimated in subjects with T1D  and T2D  on both the blinded and unblinded 
CGM.  The final secondary objective will estimate the average number of MSBD events per month in subjects with T1D  or T2D  using data obtained from the blinded and unblinded CGM 
phases of the study.  
9.1.3.  Exploratory Asses sments  
Study IOQV will possibly explore  6 different PRO evaluations that the subject will perform at 
time points outlined in the SOA ( Table IOQV. 1).  These PRO evaluations are the Hyp oglycemi c 
Confidence Scale (HCS), Adult Low Blood Sugar Survey  (ALBSS) , the Big Five Inventory  
(BFI) , Health Problem Solving Scale  (HPSS) , the Pictorial Re presentation of Illness and Self 
Measure Revised II  (PRISM R II) , and the General Life Stress Scale (GLSS) .  The details of 
each PRO evaluation are listed in the following sections.  
9.1.3.1.  Hypoglycemi c Confidence Scale  
The HCS examines the degree to which people with diabetes feel able, secure, and comfortable regarding their ability to stay safe from hypoglycemic -related problems  (Polonsky et al. 2017) .  
The HCS has been validated for use in adults with T1D and insulin- using T2D patients.  This 
evaluation uses the Likert scale with ratings of not confident at all, a little confident, moderately 
confident, and very confident to rate a subject’s response to 9 items during the evaluation (8 items for subjects without a partner and 9 for subjects with a partner) .  Each item will receive a 
score from 1 to 4 based on the subject’s response .  Scores are calculated as the sum total item 
score divided by the number of items completed ( 8 items for participants without a partner and 
9 for participants with a partner) .  Higher scores mean  greater confidence (Polonsky et al . 2017) .   
9.1.3.2.  Adult Low Blood Sugar Survey  
The ALBSS is an evaluation of the fear  of hypoglycemia  derived from the widely used and 
validated  ALBSS .  This evaluation uses the Likert scale of 0 (“never”) to 4  (“almost always ”) to 
rate 11 items  (Behavior domain with 5 items; Worry domain with 6 items) .  A h igher total score 
means greater fear (Cox et al. 1987; Grabman et al. 2017). 
9.1.3.3.  The Big Five Inventory  
The BFI is 44- item inventory that measures an individual on the Big Five Factors (dimensions) 
of personality , Extraversion  versus introversion (8 items) , Agreeableness  versus antagonism 
(9 items) , Conscientiousness  versus lack of direction (9 items) , Neuroticism  versus emotional 
stability (8 items) , and Openness  versus closedness to experience (10 items) .  Identifying a 
patient’s thinking, feeling , and behaving  may help clinicians avoid suggesting solutions that will 
not work for that patient’s personality type  (APA WWW) .  The evaluation uses a Likert scale of 
(1) disagree  strongly , (2) disagree a little, (3) neither agree nor disagree, (4) agree a little, and 
(5) agree strongly. (Goldberg 1981).  
F3Z- MC-IOQV(a)  Clinical Protocol  Page 29 
LY8888AT     Confidential      Dated: 17 Nov 2017  
 9.1.3.4.  Health Problem Solving Scale  
Patient problem -solving has been shown to be a predictor of coping and health behaviors and 
was related to imp roved outcomes in diabetes (Glasgow  et al.  2007) .  The HPSS can be used to 
“identify patients who may be most in need of problem -solving interventions as part of patient 
education and disease self -management training ” (Hill- Briggs et al . 2007) .  It is of interest to 
evaluate a person’s problem -solving abilities in association with the number of and/or frequency 
of missed mealtime  insulin doses.   
The scale is a set of 50 items that the subject rates using a 5 -point Likert scale ranging f rom “not 
at all true of me” (0 points) to “extremely true of me” (4 points).  Seven s ubscale scores are 
calculated by summing scores for each item in the respective subscale.  The HPSS total score is 
derived by using the sums of the subscale averages, with reverse scoring of the negative subscales.  Higher subscal e scores indicate more of a problem -solving characteristic.  A higher 
total HPSS score indicates a more effective health -related problem -solving skill (Hill- Briggs et 
al. 2007). 
9.1.3.5.  Pictorial Represent ation of Illness and Self Measure Revised II  
The PRISM R II  is a visual representation of burden of suffering from  diabetes in a patient’s life.  
This evaluation allows for discussion on the importance  of diabetes in the patient’s life that may 
provide ins ight into any barriers to successful diabetes management.   
The PRISM R II  consists of a large white  paper  circle, representing the subjects ’ life, with a 
yellow paper circle placed in the middle and in front /on top of  the white circle, representing the 
respondents ’ self.  Three differently sized red paper circles  represent  the respondents ’ diabetes .  
The diabetes circles  are respectively smaller than, equal to, and large r than the self circle.  
Subject s are given the following  written instruction :  “The white circle represents your current 
life and the yellow circle represents you.  The three red circles represent your diabetes.  Select 
from the three red circles the one that , in your view, represents your diabetes most accurately.  
Place the circle into your life.  Locate the circle at the place that the diabetes occupies in your 
life.  You can place the circle  anywhere in your life, also entirely or partially on top of your self.”   
Two measures are extracted from the PRISM R II , Self Illness S eparation where greater 
distances correspond to less burden and the Illness Perception Measure ranging from 1 to 3  with 
1 representing the smallest disk  (Klis et al. 2008) .  
9.1.3.6.  General Life Stress Scale  
The GLSS assesses the degree of stress an individual is currently experiencing in 5 general areas 
of life (finance, work, their romantic relationship, family, and health problems —modified to 
inquire about health problems other than diabetes)  within 6 items , with response opti ons ranging 
from 0 (“ none ”) to 4 ( “a great deal ”).  The total score is calculated, with higher scores reflecting 
greater overall life stress  (Hessler et al. 2016) . 
9.1.4.  Appropriateness of Assessments  
The objective collection of bolus dosing data using the pen will help to better understand actual 
dosing be havior.  The use of the commercially available CGM device will provide an assessment 
F3Z- MC-IOQV(a)  Clinical Protocol  Page 30 
LY8888AT     Confidential      Dated: 17 Nov 2017  
 of blood glucose control to better understand the relationship with bolus dosing.  The PROs will 
allow a better understanding of patient’s behavior  and the relationship wi th bolus dosing.  
9.2. Adverse Events and Device Complaints  
Investigators are responsible for monitoring the safety of subject s who have entered this study 
and for alerting Lilly or its designee to any event that seems unusual, even if this event may be considered an unanticipated benefit to the  subject .  The investigator is responsible for the 
appropriate medical care of  subject s during the study.  Investigators must document their review 
of each laboratory safety report.  
The investigator remains responsible for following, through an appropriate health care option, AEs that are serious or otherwise medically important, considered related to the investigational 
product or the study, or that caused the  subject  to discontinue the investigational product before 
completing the study.  The  subject  should be followed until the event resolves, stabilizes with 
appropriate diagnostic evaluat ion, or is reasonably explained.  The frequency of follow -up 
evaluations of the AE is left to the discretion of the investigator.   Lack of drug effect is not an 
AE in clinical studies . 
Hypoglycemia, as outlined in Section 9.2.1.1, should be considered an AE when reported by the study participant.  
After the informed consent form ( ICF) is signed, study site personnel will record via  the case 
report form (CRF ) the occurrence and nature of each  subject ’s preexisting conditions, including 
clinically significant signs and symptoms of the disease under treatment in the study.   In 
addition, site personnel will record any change in the condition(s) and any new conditions as 
AEs.  Investigators should record their assessment of the potential relatedness of each AE to 
protocol procedure, investigational device, or investigational product, via CRF.  
The investigator will interpret and document whether or not an AE has a reasonable possibility 
of being related to study treatment, investigational study device, or a study procedure, taking into 
account the disease, concomitant treatment , or pathologies.   
A “reasonable possibility” means that there is a cause and effect relationship between the investigational product, investigational study device and/or study procedure , and the AE.  
The investigator answers yes/no when making this assessment.  If relatedness to study device is 
“yes”, a product complaint will also ne ed to be submitted. 
Planned surgeries and nonsurgical interventions should not be reported as AEs unless the underlying medical condition has worsened during the course of the study.  
If a subject ’s investigational product is discontinued as a result of an AE, study site personnel 
must report this to Lilly or its designee via  CRF , clarifying if possible, the circumstances leading 
to any dos age modifications, or discontinuations of treatment.   
9.2.1.  Serious Adverse Events  
An SAE is any AE from this study that results in one of the following outcomes:  
F3Z- MC-IOQV(a)  Clinical Protocol  Page 31 
LY8888AT     Confidential      Dated: 17 Nov 2017  
 • death  
• initial or prolonged subject  hospitalization  
• a life -threatening experience ( i.e., immediate risk of dying)  
• persistent or significant disability/incapacity  
• congenital anomaly/birth defect  
• important  medical events that may not be immediately life threatening  or result in 
death or hospitali zation but may jeopardi ze the subject  or may require 
intervention to prevent one of the other outcomes listed in the definition above.  
Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in subject  hospitalization, or the development of 
drug dependency or drug abuse.  
• when  a condition related to the  pen necessitates medical or surgical intervention 
to preclude either permanent impairment of a body function or permanent damage to a body structure, the serious outcome of “required intervention” will be 
assigned.  
• severe hypogl ycemia  
All AEs occurring after signing the ICF are recorded in the CRF and assessed for serious criteria.  
The SAE reporting to the sponsor begins after the  subject  has signed the ICF and has received 
investigational product.  However, if an SAE occurs aft er signing the ICF, but prior to receiving 
investigational product, the SAE should be reported to the sponsor as per SAE reporting 
requirements and timelines (see Section  9.2) if it is considered reasonably possibly related to 
study procedure.  
Study site personnel must alert Lilly or its designee of any SAE within 24 hours of investigator awareness of the event via a sponsor -approved method.  If alert s are issued via telephone, they 
are to be immediately followed with official notification on study -specific SAE forms.  This 
24-hour notification requirement refers to the initial SAE information and all follow -up SAE 
information.  Subject s with a serious hepatic AE  should have additional data collected using the  
CRF . 
Pregnancy ( during maternal or paternal exposure to investigational product) does not meet the 
definition of an AE.  However, to fulfill regulatory requirements , any pregnancy should be 
reported following the SAE process to collect data on the outcome for both mother and fetus.  
Investigators are not obligated to actively seek AEs or SAEs in subjects once they have 
discontinued and/or completed the study (the  subject  disposition CRF has been completed).  
However, if the investigator learns of any SAE, including a death, at any time after a subject has been discharged from the study, and he/she considers the event reasonably possibly related to the study treatment or study participation, the investigator must promptly notify Lilly.  
F3Z- MC-IOQV(a)  Clinical Protocol  Page 32 
LY8888AT     Confidential      Dated: 17 Nov 2017  
 9.2.1.1.  Severe Hypoglycemia 
Severe hypoglycemia is defined as an event accompanied by neuroglycopenic symptoms  that 
result in cognitive impairment such that the patient requires assistance of  another person to 
actively administer carbohydrate, glucagon, or perform other  resuscitative actions .  During these 
episodes, the patient has an altered mental  status, and cannot assist in their care, is semiconscious 
or unconscious, or  experienced coma with or without seizures , and may require parenteral 
therapy.   Plasma glucose measurements may not be available during such an event, but  
neurological recovery attributable to the restoration of  self-monitored blood glucose  (SMBG ) 
concentration to normal is considered sufficient evidence that the event was induced by a low  
SMBG concentration ( ≤70 mg/dL).  
Documented symptomatic hypoglycemia is defined as an event that is accompanied by 
signs/symptoms of hypoglycemia, and is accompanied by a measured SMBG concentration of ≤70 mg/dL.  
9.2.1.2.  Suspected Unexpected Serious Adverse Reactions  
Suspected unexpected serious adverse reactions (SUSARs) are serious events that are not listed in the USPI and that the investigator identifies as related to investigational product (s) or 
procedure.  Lilly ha s procedures that will be followed for the identification , recording , and 
expedited reporting of SUSARs that are consistent with global regulations and the associated detailed guidances.  
9.2.2.  Adverse Device Effects  
The investigator is responsible for sending  to the sponsor within 24 hours  any and/or associated 
product c omplaints involving a device malfunction  of the pen, using the AE process and 
associated complaint report.   Lilly will investigate all (S)AEs and associated complaints to 
determine the extent to w hich the event was  caused by, or associated with , the investigational 
device.  
Lilly will follow procedures consistent with US regulations to confirm and handle any unanticipated adverse device effects (UADEs) , and  will inform the Food and Drug 
Administration  of confirmed UADEs following an investigation of the event .  Within 10 working 
days of learning of the event, the principal investigator will then report evaluation results for any UADE to all reviewing Institutional Review Boards.    
All UADEs will be summarized in the final study report.  
9.2.3.  Complaint Handling  
Lilly collects product complaints on investigational products and drug delivery systems used in clinical studies in order to ensure the safety of study participants, monitor quality, and to facilitate process and product improvements. 
Specifically, a product complaint is an expressed (written or verbal) statement regarding a 
deficiency in the expected performance of the device (e.g., did not work as intended; malfunctioned; difficult to us e).  A product  complaint may occur independently from an AE, or 
along with an AE .  A product complaint may also occur independently of a device malfunction.  
F3Z- MC-IOQV(a)  Clinical Protocol  Page 33 
LY8888AT     Confidential      Dated: 17 Nov 2017  
 The site is responsible for collecting all product complaints and reporting these to the sponsor  via 
the provided product complaint form template .  Device malfunctions on any Lilly product 
(e.g., failure of the investigational device to perform as intended) will be reported to the s ponsor , 
irrespective of whether associated with an AE .  
The i nvestigator must instruct  subjects  to contact the  clinical site  as soon as possible if he or she 
has a complaint or problem with the product , investigational reusable insulin injection  pen, or the 
commercially available CGM device so that the situation can  be assessed.  
All investigational reusable devices associated with complaints must be returned to the s ponsor 
for evaluation. 
9.3. Treatment of Overdose  
Refer to product labeling for insulin lispro 100 units/mL  (USPI) . 
9.4. Safety  
9.4.1.  Laboratory Tests  
For each  subject , the local laboratory test for HbA1c should be conducted according to the  SOA 
(Table IOQV. 1).  A pregnancy test may be performed at the investigator’s discretion if there is 
suspicion of possible pregnancy.  
9.4.2.  Safety Monitoring  
Lilly will periodically review evolving aggregate safety data within the study by appropriate 
methods. 
F3Z- MC-IOQV(a)  Clinical Protocol  Page 34 
LY8888AT     Confidential      Dated: 17 Nov 2017  
 10. Statistical Considerations  
10.1.  Sample Size Determination  
Approximately 68 subject s may be entered (i.e., signed informed consent)  in order that 50 
subject s complete the study .  Subject s who are entered  but not administered treatment may be 
replaced to ensure that enough subject s may complete the study.   Assuming  a screen fail rate of 
15%, the expected number of subjects to be screened is 80. Up to 15 subjects may be enrolled at 
each investigator site.  
A sample size of 50 completers  (approximately 25  subjects with  T1D  and 25 subjects with T2D ) 
is considered sufficient for this exploratory  study . 
10.2.  Populations for Analyses  
For purposes of analysis, the following analysis sets are defined:  
Table IOQV.4 . Analysis Sets  
Analysis Set  Description  
Entered  All participants who sign ed informed consent  
Evaluable  All enrolled subject s with ≥2 -week use of unblinded CGM  
Safety  All enrolled subject s with any CGM or pen usage  
Abbreviation:  CGM = continuous glucose monitoring . 
10.3.  Statistical Analyses  
10.3.1.  General Statistical Considerations  
Statistical analysis of this study will be the responsibility of Lilly o r its designee.  
Efficacy  analyses will be conducted on the  evaluable analysis set and safety analyses on the 
safety analysis set defined in Table IOQV. 4. 
Given the exploratory  nature of the study, the analyses will be primarily descriptive, using 
descriptive statistics ( mean, standard deviation [ SD], min imum, median, and max imum for 
continuous variables ; frequency and percentage for categorical variables ) or graphs (e.g., scatter 
plot).   
Missed bolus doses and glucose time -in-range will be calculated for Weeks 3 -6 for Study 
Period  1 (blinded CGM) and Weeks 9- 12 for Study Period 2 (unblinded C GM).  
Any change to the data analysis methods described in the protocol will require an amendment 
ONLY if it changes a principal feature of the protocol.  Any other change to the data analysis methods described in the protocol, and the justification for making the change, will be described in the clinical study report (CSR) .  Additional exploratory analyses of the data will be conducted 
as deemed appropriate.  
F3Z- MC-IOQV(a)  Clinical Protocol  Page 35 
LY8888AT     Confidential      Dated: 17 Nov 2017  
 10.3.1.1.  Treatment Group Comparability  
10.3.1.2.  Subject  Disposition  
The primary reasons for discontinuation will be  summarized by s tudy period and subject  
allocation will be summarized by investigative site  for the entered  analysis set . 
10.3.1.3.  Subject  Characteristics  
Baseline characteristics will be summarized for the e ntered  analysis set and the e valuable 
analysis set.  
10.3.1.4.  Treat ment Compliance  
Amount of useable data from the CGM device and pen will be summarized for the e valuable 
analysis set.  
10.3.2.  Efficacy Analyses  
10.3.2.1.  Primary Analyses 
The average number of days per month with a missed bolus dose during the last 3 weeks of 
Study Period 1 will be summarized.   The 3 weeks of data will be adjusted  to a 1-month interval , 
and a  95% confidence interval will be calculated.  
10.3.2.2.  Secondary Analyses 
The percent  glucose time -in-range (>70 and ≤180 mg/dL) will be calculated and summarized for 
Study Period 1 and Study Period 2.  The number of missed bolus  doses (average number of  
missed bolus doses per day) as well as the percent of missed bolus doses (adjusted to a 1- month 
interval) will be summarized by Study Period 1 and Study Period 2.  The MSBD will be  
summarized by Study Period 1 and Study Period 2.  
10.3.3.  Safety Analyses  
Adverse events  including discontinuations due to AEs  and SAEs will be summarized .   
10.3.4.  Other Analyses  
Patient reported outcomes  rated on the Likert scale will be summarized using frequency and 
percentage.  Domain or total scores will be summarized  using :  n, mean, SD , minimum, median,  
maximum at the times outlined in the SOA ( Table IOQV. 1).   
In addition, bolus dose , basal insulin dose information, and exposure will be summarized.   
10.3.4.1.  Subgroup Analy ses 
The average number of missed bolus doses  per month will be summarized for the  following 
baseline subgroups:    
• Glucose time -in-range (≤median vs. >median);  
• HbA1c (≤9.0% vs. >9.0 %); 
• Duration of diabetes (≤median vs. >median) ; 
• Prior CGM experience (yes vs. no).  
F3Z- MC-IOQV(a)  Clinical Protocol  Page 36 
LY8888AT     Confidential      Dated: 17 Nov 2017  
 10.3.5.  Interim Analyses  
No interim analyses are planned for this study.   
F3Z- MC-IOQV(a)  Clinical Protocol  Page 37 
LY8888AT     Confidential      Dated: 17 Nov 2017  
 11. References  
Al-Qazaz HKh, Sulaiman SA, Hassali MA, Shafie AA, Sundram S, Al -Nuri R, Saleem F. 
Diabetes knowledge, medication adherence and glycemic control among patients  with type 2 
diabetes. Int J Clin Pharm . 2011;33(6):1028- 1035.  
[APA] American Psycholo gical Association. Personality. Available at 
http://www.apa.org/topics/personality/ . Accessed on 25 July 2017.  
Burdick J, Chase HP, Slover RH, Knievel K, Scrimgeour L, Maniatis AK, Klingensmith GJ. 
Missed insulin meal boluses and elevated hemoglobin A1c le vels in children receiving insulin 
pump therapy. Pediatrics.  2004;113(3 Pt 1):e221- 224. 
Cox DJ, Irvine A, Gonder -Frederick L, Nowacek G, Butterfield J. Fear of hypoglycemia: 
quantification, validation, and utilization. Diabetes Care . 1987;10(5):617- 621. 
Cummings DM, Lutes L, Littlewood K, DiNatale E, Hambidge B, Schulman K, Morisky DE. 
Regimen -Related Distress, Medication Adherence, and Glycemic Control in Rural African 
American Women With Type 2 Diabetes Mellitus.  Ann Pharmacother . 2014;48(8):970- 977. 
Glasgow RE, Fisher L, Skaff M, Mullan J, Toobert DJ. Problem solving and diabetes self -
management : investigation in a large, multiracial sample. Diabetes Care . 2007;30(1):33- 37. 
Goldberg LR. Language and individual differences : The search for universals in per sonality 
lexicons. Review of Personality and Social Psychology. 1981; 2:141- 165. 
Gonzalez JS, Shreck E, Psaros C, Safren SA. Distress and type 2 diabetes -treatment adherence: 
A mediating role for perceived control. Health Psychol. 2015;34(5):505- 513. 
Grabman J, Vajda Bailey K, Schmidt K, Cariou B, Vaur L, Madani S, Cox D, Gonder -Frederick 
L. An empirically derived short form of the Hypoglycaemia Fear Survey II. Diabet Med . 
2017;34(4):500- 504. 
Hessler D, Fisher L, Polonsky  W, Johnson N. Understanding the Areas and Correlates of 
Diabetes -Related Distress in Parents of Teens With Type 1 Diabetes. J Pediatr Psychol.  
2016;41(7):750- 758. 
Hill- Briggs F, Gemmell L, Kulkarni B, Klick B, Brancati FL. Associations of patient health -
related problem solving with disease control, emergency department visits, and 
hospitalizations in HIV and diabetes clinic samples. J Gen Intern Med.  2007;22(5):649- 654. 
Klis S, Vingerhoets AJ, de Wit M, Zandbelt N, Snoek FJ. Pictorial Representation of Ill ness and 
Self Measure Revised II (PRISM -RII): a novel method to assess perceived burden of illness in 
diabetes patients. Health Qual Life Outcomes. 2008;6:104. 
Peyrot M , Barnett AH , Meneghini LF , Schumm -Draeger  PM.  Insulin adherence behaviours and 
barriers  in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy 
study . Diabet Med. 2012;5(29) :682-689. 
Polonsky W H, Fisher L, Hessler D, Edelman SV. Investigating Hypoglycemic Confidence in 
Type  1 and Type 2 Diabetes. Diabetes Technol Ther . 2017;19(2):131- 136.  
 
 
F3Z- MC-IOQV(a)  Clinical Protocol  Page 38 
LY8888AT     Confidential      Dated: 17 Nov 2017  
  
 
F3Z- MC-IOQV(a)  Clinical Protocol  Page 39 
LY8888AT     Confidential      Dated: 17 Nov 2017  
 12. Appendices  
F3Z- MC-IOQV(a)  Clinical Protocol  Page 40 
LY8888AT     Confidential      Dated: 17 Nov 2017  
 Appendix 1.  Abbreviations and Definitions  
Term  Definition  
AE adverse event:  Any untoward medical occurrence in a subject  or clinical investigation 
subject administered a pharmaceutical product that does not necessarily have a causal 
relationship with this treatment.  An AE can therefore be any unfavorable and 
unintended sign (including an abnormal laboratory finding), sympt om, or disease 
temporally associated with the use of a medicinal (investigational) product, whether or 
not related to the medicinal (investigational) product.  
ALBSS  Adult Low Blood Sugar Survey  
BFI The Big Five Inventory  
CGM  continuous glucose monitoring  
CIOMS  Council  for International  Organizations  of Medical  Sciences  
complaint  A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system.  
compliance  Adherence to all study -related, good clinical practice (GCP), and applicable regulatory 
requirements.  
CRF case report form  
CSR clinical study report 
enroll  The act of assigning  a subject  to a treatment.  Subject s who are enrolled in the study are 
those who have been assigned to a treatment.  
enter  Subject s entered into a study are those who sign the informed consent form directly or 
through their legally acceptable representatives.  
ERB ethical review board  
FOIA  Freedom of Information Act  
GCP  good clinical practice  
GLSS  General Life Stress Scale 
HbA1c  glycated hemoglobin  
HCS  Hypoglycemic Confidence Scale 
HPSS Health Problem Solving Scale 
IB Investigator’s Brochure  
F3Z- MC-IOQV(a)  Clinical Protocol  Page 41 
LY8888AT     Confidential      Dated: 17 Nov 2017  
 Term  Definition  
ICF informed consent form  
ICH International Council for Harmonisation  
Informed consent  A process by which a  subject  voluntarily confirms his or her willingness to participate 
in a particular study, after having been informed of all aspects of t he study that are 
relevant to the subject ’s decision to participate.  Informed consent is documented by 
means of a written, signed and dated informed consent form.  
investigational 
product  A pharmaceutical form of an active ingredient or placebo being test ed or used as a 
reference in a clinical trial, including products already on the market when used or 
assembled (formulated or packaged) in a way different from the authorized form, or 
marketed products used for an unauthorized indication, or marketed produ cts used to 
gain further information about the authorized form.  
IOQV  F3Z-MC-IOQV  
Malfunction  Any failure of a device to meet its performance specifications or otherwise perform as intended .  Performance specifications include all claims made in the labeling for the 
device.  The intended performance of a device refers to the intended use for which the device is labeled or marketed.  
MSBD missing and suboptimal bolus dose  
PRISM R II  Pictorial Representation of I llness and S elf Measure Revised II  
PRO/ ePRO  patient -reported outcomes/electronic patient -reported outcomes  
SAE serious adverse event  
screen  The act of determining if an individual meets minimum requirements to become part of a pool of potential candidates for participation in a clinical study.  
SD standard deviation  
SMBG  self-monitored blood glucose  
SOA  Schedule of Activities  
SUSARs  suspec ted unexpected serious adverse reactions  
T1D type 1 diabetes  
T2D type 2 diabetes  
UADE  Unanticipated Adverse Device Effect:  Any serious adverse effect on health or safety or 
any life -threatening problem or death caused by, or associated with, a device, if that 
effect, problem, or death was not previously identified in nature, severity, or degree of 
incidence in the investigational plan or application (including a supplementary plan or 
application), or any other unanticipated serious problem associated wi th a device that 
relates to the rights, safety, or welfare of subjects.  
F3Z- MC-IOQV(a)  Clinical Protocol  Page 42 
LY8888AT     Confidential      Dated: 17 Nov 2017  
 Term  Definition  
US United States  
USPI  United States Package Insert  
F3Z- MC-IOQV(a)  Clinical Protocol  Page 43 
LY8888AT     Confidential      Dated: 17 Nov 2017  
 Appendix 2.  Study Governance Considerations  
Appendix  2.1. Regulatory and Ethical Considerations, Including the 
Informed Consent Process  
Appendix 2.1.1. Informed Consent  
The investigator is responsible for:  
• ensuring that the  subject  or the subject ’s legal representative u nderstands  the 
nature of the study , the potential risks and benefits of participating in the study , 
and that their participation is voluntary . 
• ensuring that informed consent is given by each subject  or legal representative.  
This includes obtaining the appropriate signatures and dates on the informed 
consent form ( ICF) prior to the performance of any protocol procedure s and 
prior to the administration of investigational product. 
• answering any questions the subject  or the subject ’s legal representative may 
have throughout the study and sharing in a timely manner any new information that may be relevant to the subject ’s or the subject ’s legal representative’s 
willingness to continue his or her participation in the study.  
• ensuring that a copy of the ICF is provided to the participant or the participant’s legal representative and is kept on file.  
• ensuring that the medical record includes a statement that written informed consent was obtained before the participant was enrolled in the study and the 
date the written consent was obtained.  The authorized person obtaining the 
informed consent must also sign the ICF.  
Appendix 2 .1.2. Recruitment  
Lilly is  responsible for the central recruitment strategy for subject s.  Individual investigators may 
have additional local requirements or processes.  
Appendix 2 .1.3. Ethical Review  
The investigator  or an appropriate local representative  must give assurance that the ethical 
review board (ERB) was properly constituted and convened as required by International Council  
for Harmonisation (ICH) guidelines and other applicable laws and regulations . 
Documentation of ERB approval of the protocol a nd the ICF must be provided to Lilly before the 
study may begin at the investigative site(s).  Lilly or its representatives must approve the ICF, 
including any changes made by the ERBs, before it is used at the investigative site(s).  All ICFs must be compliant with the ICH guideline on Good Clinical Practice ( GCP ). 
  
F3Z- MC-IOQV(a)  Clinical Protocol  Page 44 
LY8888AT     Confidential      Dated: 17 Nov 2017  
 The study site’s ERB(s) should be provided with the following:  
• the protocol and related amendments and addenda , current Investigator’ s 
Brochure , United States Product Information , training checklist, and updates 
during the course of the study  
• the ICF  
• other relevant documents ( for example, curricula vitae, advertisements)  
Appendix 2 .1.4. Regulatory Considerations  
This study will be conducted in accordance with the protocol and with the : 
• consensus ethics principles derived from international ethics guidelines, including 
the Declaration of Helsinki and Council for International Organizations of 
Medical Sciences (CIOMS) International Ethical Guidelines  
• applicable ICH GCP Guidelines  
• applicable laws and regulations  
Some of the obligations of the sponsor will be assigned to a third party.  
Appendix 2 .1.5. Investigator Information 
Physicians with a specialty in  endocrinology, diabetology, and/or primary care will participate as 
investigators  in this clinical trial.  
Appendix 2 .1.6. Protocol Signatures  
The sponsor’s responsible medical officer will approve the protocol, confirming that, to the best 
of his or her knowledge, the protocol accurately describes the planned design and conduct of the study.  
After reading the protocol, each principal investigator will sign the protocol signature page and send a copy of the signed page to a Lilly representative.  
Appendix 2 .1.7. Final Report Signature  
The investigator will sign the final clinical study re port (CSR) for this study, indicating 
agreement with the analyses, results, and conclusions of the report.  
The sponsor’s responsible medical officer and statistician will approve the final CSR for this 
study, confirming that, to the best of his or her know ledge, the report accurately describes the 
conduct and results of the study.  
Appendi x 2.2. Data Quality Assurance  
To ensure accurate, complete, and reliable data, Lilly or its representatives will do the following:  
• provide instructional material to the study sites, as appropriate  
F3Z- MC-IOQV(a)  Clinical Protocol  Page 45 
LY8888AT     Confidential      Dated: 17 Nov 2017  
 • sponsor start -up training to instruct the investigators and study coordinators.  This 
training will give instruction on the protocol, the completion of the case report 
forms (CRFs ), and study procedures.  
• make periodic visits to the study site  
• be available for consultation and stay in contact with the study site personnel by mail, telephone, and/or fax 
• review and evaluate CRF data and use standard computer edits to detect errors in 
data collection  
• conduct a quality review of the database  
In addition, Lilly or its representatives will periodically check a sample of the  subject  data 
recorded against source documents at the study site.  The study may be audited by Lilly or its 
representatives, and/or regulatory agencies at any time.  Investigators will be given notice before 
an audit occurs.  
The investigator will keep records of all original source data.  This might include laboratory tests, medical records, and clinical notes.  If requested, the investigator will provide the sponsor, applicable regulatory agencies, and applicable ERBs with direct access to original source documents. 
Appendix 2.2.1. Data Capture System  
An electronic data capture system will be used in this study.  The site maintains a separate source 
for the data entered by the site into the sponsor -provided electronic data capture system.  
Paper and electronic patient -reported outcome s (ePRO) measures or other data reported directly 
by the  subject  are entered into an ePRO instrument  at the time that the information is obtained.  
In these instances where there is no prior written or electronic source data at the site, the ePRO instrument record will serve as the source.  
If ePRO records are stored at a third -party site, investigator sites will have continuous access to 
the source documents during the study and will receive an archival copy at the end of the study for retention.  
Any data for which the ePRO instrument record will serve to collect source data will be identified and document ed by each site in that site’s study file . 
Case report form data will be encoded and stored in a clinical trial database.  
Case report form data collected by a third party  will be encoded by the third party  and stored 
electronically in the third -party’s dat abase system.  Validated data will subsequently be 
transferred to  the sponsor’s data warehouse using standard Lilly file transfer processes.  
Any data for which paper documentation provided by the study participant  will serve as the 
source document will be identified and documented by each site in that site’s study file.  Paper documentation provided by the study participant may include, for example, a paper diary to 
F3Z- MC-IOQV(a)  Clinical Protocol  Page 46 
LY8888AT     Confidential      Dated: 17 Nov 2017  
 collect patient -reported outcome s measures (for example, a rating scale), a daily dosing sch edule, 
or an event diary.  
Data from complaint forms submitted to Lilly will be encoded and stored in the global product 
complaint management system.  
Appendix 2.3. Study and Site Closure  
Appendix 2 .3.1. Discontinuation of Study Sites  
Study site participation may be discontinued  if Lilly or its designee , the investigator, or the ERB 
of the study site  judges it necessary for medical, safety, regulatory, or other reasons consistent 
with applicable laws, regulations, and GCP. 
Appendix 2 .3.2. Disconti nuation of the Study  
The study will be discontinued if  Lilly or its designee  judges it necessary for medical, safety, 
regulatory, or other reasons consistent with applicable laws, regulations, and GCP. 
  
F3Z- MC-IOQV(a)  Clinical Protocol  Page 47 
LY8888AT     Confidential      Dated: 17 Nov 2017  
 Appendix 3.  Classification of Contraceptive Methods  
Highly Effective Methods of Contraception:  
• Combined oral contraceptive pill and mini -pill 
• NuvaRing 
• Implantable contraceptives  
• Injectable contraceptives (such as Depo -Provera®)  
• Intrauterine device (such as Mirena® and ParaGard®)  
• Contraceptive patch – ONLY women <198 pounds or 90 kg 
• Total Abstinence  
• Vasectomy – for men in clinical trials  
Effective Methods of Contraception (must use combination of 2 methods):  
• Male condom with spermicide  
• Female condom with spermicide  
• Diaphragm with spermicide  
• Cervical sponge  
• Cervical cap with spermicide  
Ineffective Forms of Contraception – not acceptable as a method for clinical trials  
• Spermicide alone (please note spermicide alone is not considered a barrier method)  
• Immunocontraceptives  
• Periodic abstinence  
• Fertility awareness (calen dar method, temperature method, combination of above 2, 
cervical mucus, symptothermal)  
• Withdrawal  
• Post coital douche  
• Lactational amenorrhea  
  
F3Z- MC-IOQV(a)  Clinical Protocol  Page 48  
LY8888AT     Confidential      Dated: 17 Nov 2017  
 Appendix 4.    
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
F3Z- MC-IOQV(a)  Clinical Protocol  Page 49  
LY8888AT     Confidential      Dated: 17 Nov 2017  
 Appendix 5.  Summary of Protocol Amendments  
Protocol Amendment 1, Dated 17 Nov  2017 
Section  Summary of Changes  
2 Schedule of Activities  Negative p regnancy test added as a  required  activity to be conducted 
during screening (Visit  1) 
6.1 Inclusion Criteria  [5b] Definitions of women of child -bearing potential added to the 
inclusion criteria  
Appendix 3  Classification of contraceptive methods added  
Appendix 4  –   Information on  and the use of mobile nurses  
 
CCI
CCI